JP2011528034A - アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法 - Google Patents

アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法 Download PDF

Info

Publication number
JP2011528034A
JP2011528034A JP2011518716A JP2011518716A JP2011528034A JP 2011528034 A JP2011528034 A JP 2011528034A JP 2011518716 A JP2011518716 A JP 2011518716A JP 2011518716 A JP2011518716 A JP 2011518716A JP 2011528034 A JP2011528034 A JP 2011528034A
Authority
JP
Japan
Prior art keywords
compound
heteroaryl
aryl
carbonyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011518716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528034A5 (enExample
Inventor
アンダーソン，リチャード
ブリージール，スティーヴン
エリッチ，テッド・ディー
リー，シャイ‐フー
Original Assignee
クロップソリューション，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロップソリューション，インコーポレイテッド filed Critical クロップソリューション，インコーポレイテッド
Publication of JP2011528034A publication Critical patent/JP2011528034A/ja
Publication of JP2011528034A5 publication Critical patent/JP2011528034A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2011518716A 2008-07-14 2009-07-13 アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法 Withdrawn JP2011528034A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8050408P 2008-07-14 2008-07-14
US61/080,504 2008-07-14
US12059908P 2008-12-08 2008-12-08
US61/120,599 2008-12-08
PCT/US2009/004062 WO2010008521A1 (en) 2008-07-14 2009-07-13 Modulators of acetyl-coenzyme a carboxylase and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2011528034A true JP2011528034A (ja) 2011-11-10
JP2011528034A5 JP2011528034A5 (enExample) 2012-08-16

Family

ID=41505707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518716A Withdrawn JP2011528034A (ja) 2008-07-14 2009-07-13 アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法

Country Status (6)

Country Link
US (1) US8110570B2 (enExample)
EP (1) EP2310015A4 (enExample)
JP (1) JP2011528034A (enExample)
AU (1) AU2009271634A1 (enExample)
CA (1) CA2730493A1 (enExample)
WO (1) WO2010008521A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506939A (ja) * 2013-02-04 2016-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
JP2020505348A (ja) * 2017-01-26 2020-02-20 サイクラセル リミテッド プリン誘導体を調製するための方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297163B1 (en) * 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CA2778886C (en) * 2009-11-10 2014-01-07 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
PL2632925T3 (pl) * 2010-10-29 2015-10-30 Pfizer N1/N2-laktamowe inhibitory karboksylazy acetylo-CoA
CN102532156B (zh) * 2010-12-15 2013-11-06 中国科学院昆明植物研究所 獐牙菜内酯h-k，其药物组合物及其用途
JP2014508752A (ja) * 2011-02-17 2014-04-10 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 治療用の置換３−（ビフェニル−３−イル）−８，８−ジフルオロ−４−ヒドロキシ−１−アザスピロ［４．５］デカ−３−エン−２−オン
EA022375B1 (ru) 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ
WO2016112088A1 (en) * 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
WO2019099457A1 (en) * 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
CN108276307A (zh) * 2018-01-17 2018-07-13 常熟浸大科技有限公司 3-氰基-4-烃氧基苯甲酸酯的合成方法
CN110028521B (zh) * 2019-05-27 2020-07-14 湖南科技大学 11-芳基-1,4-苯并恶嗪酮并咪唑啉类化合物及其制备方法和用途
CN113264949B (zh) * 2021-05-31 2022-04-05 西南大学 一类螺苯并噁嗪哌啶α,β-不饱和酮类衍生物的设计合成与应用
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4831114B1 (enExample) * 1970-05-22 1973-09-26
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
US7410976B2 (en) * 2005-07-19 2008-08-12 Merck & Co., Inc. Spirochromanone derivatives
JP2009256208A (ja) 2006-08-17 2009-11-05 Dainippon Sumitomo Pharma Co Ltd フタリド誘導体またはその薬学的に許容される塩
EP2097420B1 (en) 2006-11-29 2012-04-04 Pfizer Products Inc. Spiroketone inhibitors of acetyl-coa carboxylase
CA2674530C (en) 2007-01-12 2014-09-16 Banyu Pharmaceutical Co., Ltd. Spirochromanon derivatives
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506939A (ja) * 2013-02-04 2016-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
JP2020505348A (ja) * 2017-01-26 2020-02-20 サイクラセル リミテッド プリン誘導体を調製するための方法
JP7122759B2 (ja) 2017-01-26 2022-08-22 サイクラセル リミテッド プリン誘導体を調製するための方法

Also Published As

Publication number Publication date
EP2310015A1 (en) 2011-04-20
US20100009982A1 (en) 2010-01-14
US8110570B2 (en) 2012-02-07
EP2310015A4 (en) 2011-10-26
WO2010008521A1 (en) 2010-01-21
AU2009271634A1 (en) 2010-01-21
CA2730493A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
JP2011528034A (ja) アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法
US20080200461A1 (en) Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
CN101696221B (zh) 作为杀真菌剂的取代异噁唑
CN109369524A (zh) 脯氨酰羟化酶抑制剂的晶体形态
JP2006511485A (ja) ヘテロシクロカルボキサミド誘導体
JP2010507609A (ja) 新規ピリダジン誘導体
US20110224252A1 (en) Novel imidazole derivatives
TW201838974A (zh) 具殺菌性質之雜環化合物
UA127503C2 (uk) Оксадіазоли, призначені для використання у контролі фітопатогенних грибів
TW201912641A (zh) 新型殺真菌雜環化合物
CN109232469A (zh) 一类三取代噻唑酰胺衍生物及其制备方法和用途
EA019414B1 (ru) Новые микробиоциды
JPH06506441A (ja) ピペリジン誘導体
TW200932238A (en) Novel pyridazine derivatives
JP2011500749A (ja) 新規イミダゾール誘導体
RU2448104C2 (ru) Замещенные ароматические гетероциклические соединения, как фунгициды
KR20090073252A (ko) 신규한 피리다진 유도체
CN107709335A (zh) Kakeromycin及其衍生物的制造方法
TW201002203A (en) Novel imidazole derivatives
CN113278020A (zh) 含酰基硫脲结构的pityriacitrin生物碱衍生物及其制备方法和用途
CN101318976A (zh) 一种含氨基膦酸酯的氰基丙烯酸酯衍生物及其制备方法和用途
CN110759911B (zh) 咔啉衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
US5750469A (en) Subtituted lactic acid derivatives having an N-organic radical in the .beta.
CN119798201B (zh) 含7-n/o乙酰肼的香豆素类化合物及其制备方法和应用
US7541472B2 (en) 3-Aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120702

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131112